DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Acular (Ketorolac Tromethamine Ophthalmic) - News

 
 



News related to Acular (Ketorolac Ophthalmic) and/or conditions it is approved for

Macular Degeneration
Source: MedicineNet Eyeglasses, Sunglasses, and Magnifiers Specialty [2014.01.23]
Title: Macular Degeneration
Category: Diseases and Conditions
Created: 7/23/1999 6:05:00 PM
Last Editorial Review: 1/23/2014 12:00:00 AM

Jetrea Gets FDA Nod for Macular Adhesion
Source: MedPage Today Product Alert [2012.10.19]
WASHINGTON -- The FDA has approved ocriplasmin (Jetrea) as the first nonsurgical treatment for symptomatic vitreomacular adhesion.

'Miniature Telescope' for Eye Approved for Macular Degeneration
Source: MedicineNet Macular Degeneration (Age-Related Type) Specialty [2010.07.07]
Title: 'Miniature Telescope' for Eye Approved for Macular Degeneration
Category: Health News
Created: 7/6/2010 2:10:00 PM
Last Editorial Review: 7/7/2010

Three-year data from Oraya Therapeutics' INTREPID study continue to show favorable safety profile of non-invasive wet AMD therapy
Source: Eye Health / Blindness News From Medical News Today [2014.09.17]
Oraya Therapeutics Inc. has announced that full results of three-year safety follow-up data from the INTREPID study of Oraya Therapy™ for wet age-related macular degeneration (AMD) further...

Roche initiates phase III trials for lampalizumab, first potential treatment for geographic atrophy (GA)
Source: Clinical Trials / Drug Trials News From Medical News Today [2014.09.16]
Roche has announced that phase III clinical studies have been initiated for lampalizumab, an investigational drug for geographic atrophy (GA), the advanced form of age-related macular degeneration...

A spontaneous retinal neovascular mouse model
Source: Eye Health / Blindness News From Medical News Today [2014.09.08]
Neovascular age-related macular degeneration (AMD), which involves formation of abnormal blood vessels in the retina, is a leading cause of vision loss.

Ruboxistaurin (RBX) may reduce risk of vision loss in diabetics
Source: The Doctors Lounge - Endocrinology and Diabetes
Phase III trial demonstrates ruboxistaurin (RBX) may reduce the risk of vision loss especially in diabetic macular edema.

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014